Anebulo Pharmaceuticals (ANEB) to Release Quarterly Earnings on Wednesday

Posted by Editorial Team on May 19th, 2025

Anebulo Pharmaceuticals (NASDAQ:ANEB – Get Free Report) is expected to issue its Q3 2025 quarterly earnings data before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.05) per share for the quarter.

Anebulo Pharmaceuticals (NASDAQ:ANEB – Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01.

Anebulo Pharmaceuticals Stock Performance

ANEB stock opened at $1.02 on Monday. The company has a market capitalization of $41.91 million, a P/E ratio of -3.64 and a beta of -1.12. Anebulo Pharmaceuticals has a 52-week low of $0.80 and a 52-week high of $3.08. The business has a 50-day simple moving average of $1.20 and a two-hundred day simple moving average of $1.38.

Hedge Funds Weigh In On Anebulo Pharmaceuticals

An institutional investor recently bought a new position in Anebulo Pharmaceuticals stock. Goldman Sachs Group Inc. bought a new position in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 47,954 shares of the company’s stock, valued at approximately $62,000. Goldman Sachs Group Inc. owned about 0.12% of Anebulo Pharmaceuticals as of its most recent SEC filing. 28.40% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Maxim Group cut their price target on Anebulo Pharmaceuticals from $6.00 to $3.00 and set a “buy” rating for the company in a research note on Thursday.

Check Out Our Latest Stock Analysis on Anebulo Pharmaceuticals

Anebulo Pharmaceuticals Company Profile

(Get Free Report)

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.